Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.
We’re here to help you after a new T1D diagnosis. Get answers to frequently asked questions and learn about clinical studies testing ways to maintain insulin production.
While you wait for screening results, get answers to your questions, find out about next steps, and learn more about TrialNet’s Pathway to Prevention.
Your T1D families are important to you. Learn how easy it is to connect your patients with world-class T1D research.
In stage 3, the immune system has killed off a very large number of beta cells. In addition to diabetes-related autoantibodies and abnormal blood sugar levels, now the symptoms of T1D are usually present.
Thanks to nearly 160,000 TrialNet study participants to date, we now know more about T1D than ever before.
Today, T1D is better understood as an autoimmune disorder that begins years before symptoms appear.
With TrialNet screening, we can identify individuals who are in the early stages of T1D. Increased risk of developing symptomatic T1D is linked to the presence of diabetes-related autoantibodies in the blood. Having two or more of these autoantibodies is now classified as early stage T1D. Almost everyone in stage 1 and 2 will progress to stage 3 (clinical diagnosis).
In stage 3, individuals usually have the symptoms associated with T1D. This happens because the immune system has killed off a significant number of beta cells.
Even in stage 3, many people continue to make small amounts of insulin. Your body’s ability to keep making insulin, even in small amounts, is your best defense against complications and helps you better manage the disease. TrialNet offers clinical trials exploring ways to maintain beta cell function for as long as possible.
If your screening results show you are in stage 3, you may be able to participate in a clinical study for people newly diagnosed. These studies are looking for ways to maintain beta cell function as long as possible.